Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.
about
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesObstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys.Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens.Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.Rational antibody-based HIV-1 vaccine design: current approaches and future directionsA comparative study of HIV-1 clade C env evolution in a Zambian infant with an infected rhesus macaque during disease progression.Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectorsImpact of ETIF deletion on safety and immunogenicity of equine herpesvirus type 1-vectored vaccines.Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC.Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary virusesAbility of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virusEfficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructsEffect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag.A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rheAntigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogensVaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challengeHeterologous prime-boost vaccination with DNA and MVA vaccines, expressing HIV-1 subtype C mosaic Gag virus-like particles, is highly immunogenic in mice.Development of nonhuman adenoviruses as vaccine vectors.Intranasal delivery of vaccines against HIV.Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responsesAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.Neutralizing antibodies to HIV-1 induced by immunization.Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects.Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vectorDesigning tomorrow's vaccines.Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved AntigensControl of viremia and maintenance of intestinal CD4(+) memory T cells in SHIV(162P3) infected macaques after pathogenic SIV(MAC251) challenge.Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses.Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants.Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets.An overview of live attenuated recombinant pseudorabies viruses for use as novel vaccines.
P2860
Q27489000-3F3313ED-9E5A-4A73-A632-85931E22BD03Q30378897-BD9F2EAC-678C-4328-99F3-B8B2BB435C61Q30379200-AC263E7D-F6AD-4606-9D07-8A534FC05910Q30391652-CE0378E1-AD3F-4242-9340-A8742C003EDDQ33834916-378EB1FE-567E-4CE2-96FD-AF30B210FA60Q33843258-4EEBB641-A1FE-458B-B0DE-32E10315E1E2Q33930424-880FC697-C8EC-4ADA-9826-94C5EFDA3E63Q33937285-26BEF06C-7EF7-444E-A7B0-774089189D67Q33980469-9052799E-4F83-417F-86A2-2F9AEC0CBC68Q34204440-91F69937-9D9E-451D-8678-0E18A6C71F74Q34296144-B909CD73-5930-4C8B-A7A8-12DD49E3E0EFQ34357068-CF4DAAB8-B9EE-4AB7-A84E-0B1B53CFEB02Q34648342-9ACCD2D3-DF57-4AEF-8D0A-63B45BC09080Q35569049-34414D4C-BEDB-487D-AC59-23D705CA53F9Q35675044-AC29AFD0-D090-45F9-8659-BE7159F3A83AQ35677724-9956A75F-5384-4D96-A987-15E366372805Q35750430-98084D04-C3A2-482A-BEB1-59059FE3D9BCQ35785031-364865A3-5F05-4382-86CE-0673832E9548Q35933555-87486155-8D6B-400A-9073-E30620E494BDQ36138144-0CC11CA6-FDE0-4FF4-B10B-CFE7342AF5C8Q36228649-1E73AFC2-688A-432B-A698-216DB1D0851DQ36302688-AA3556D1-A074-463D-B66D-82F64F1B889AQ36317264-1DD5CBDE-ED34-4152-A423-95DC25B3B076Q36409054-827D4107-4E7C-4903-97E3-34DD92E294C7Q36424574-C2261D2A-D90D-43B7-BAAF-5B78EE15AEE5Q36600380-BD55BC43-2B64-4514-87CC-B19ABBF082B4Q36603515-446931F7-99C8-402C-8815-7055432B2A93Q36628032-4AB383A9-280A-495D-9383-0290EDC80EB8Q36720978-6C82DC01-B9BE-4D01-8D1E-A2E34091E779Q36720991-C88C1502-A8EA-42B8-8A69-BCEBA905DE05Q36730618-AF646CCA-F234-4ECE-A007-15BDBAE027FAQ36736400-C8FD1DBD-CAC5-49FA-9D74-FFA31D237619Q37171639-874D1B75-8F33-4889-96E3-77F2DF21A15DQ37191912-EE369999-02B7-451D-8A41-EFB374E452EFQ37247974-884CB80E-38E3-4019-9807-CF8DEA63C788Q37276912-65CBE194-8F79-4DA8-8FBF-909EE7A4FDA5Q37297052-D0CCDE06-0E48-4AE1-B8A0-BC1CCB60B991Q37329415-B5150DA2-9951-4FF3-8C89-8729C3652AEFQ38096489-A6FDD3BF-E4FA-4551-A27C-A044629C3BBFQ38226289-D1E8825E-8C6D-4174-BF72-AAFBC6285E0A
P2860
Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2005
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Neutralizing antibodies elicit ...... iciency virus type 1 proteins.
@en
Neutralizing antibodies elicit ...... iciency virus type 1 proteins.
@nl
type
label
Neutralizing antibodies elicit ...... iciency virus type 1 proteins.
@en
Neutralizing antibodies elicit ...... iciency virus type 1 proteins.
@nl
prefLabel
Neutralizing antibodies elicit ...... iciency virus type 1 proteins.
@en
Neutralizing antibodies elicit ...... iciency virus type 1 proteins.
@nl
P2093
P2860
P50
P921
P1433
P1476
Neutralizing antibodies elicit ...... iciency virus type 1 proteins.
@en
P2093
Anna Sambor
Bimal K Chakrabarti
Brent Welcher
Kristin Beaudry
Mark K Louder
Norman L Letvin
Sampa Santra
Thomas C Vancott
Wing-Pui Kong
P2860
P304
P356
10.1128/JVI.79.2.771-779.2005
P407
P577
2005-01-01T00:00:00Z